Cargando…

Alteration of Energy Substrates and ROS Production in Diabetic Cardiomyopathy

Diabetic cardiomyopathy is initiated by alterations in energy substrates. Despite excess of plasma glucose and lipids, the diabetic heart almost exclusively depends on fatty acid degradation. Glycolytic enzymes and transporters are impaired by fatty acid metabolism, leading to accumulation of glucos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzo, O., Ramírez, E., Picatoste, B., Egido, J., Tuñón, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833358/ https://www.ncbi.nlm.nih.gov/pubmed/24288443 http://dx.doi.org/10.1155/2013/461967

Ejemplares similares

Potential Role of Nuclear Factor κB in Diabetic Cardiomyopathy
por: Lorenzo, O., et al.
Publicado: (2011)

Updating Experimental Models of Diabetic Cardiomyopathy
por: Fuentes-Antrás, J., et al.
Publicado: (2015)

Diagnostic approaches for diabetic cardiomyopathy
por: Lorenzo-Almorós, A., et al.
Publicado: (2017)

Targeting metabolic disturbance in the diabetic heart
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2015)

Activation of Toll-Like Receptors and Inflammasome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation
por: Fuentes-Antrás, J., et al.
Publicado: (2014)

Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms
por: Picatoste, Belén, et al.
Publicado: (2013)

Correction: Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms
por: Picatoste, Belén, et al.
Publicado: (2013)

Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking
por: Ramírez, E., et al.
Publicado: (2018)

Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases
por: Lorenzo-Almorós, A., et al.
Publicado: (2019)

Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes
por: Ramírez, Elisa, et al.
Publicado: (2013)

Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy
por: Kaludercic, Nina, et al.
Publicado: (2020)

Mitochondrial Reactive Oxygen Species (ROS) Production Alters Sperm Quality
por: Chianese, Rosanna, et al.
Publicado: (2021)

Effects of altered cellular ultrastructure on energy metabolism in diabetic cardiomyopathy: an in silico study
por: Ghosh, Shouryadipta, et al.
Publicado: (2022)

Microvesicles: ROS scavengers and ROS producers
por: Bodega, G., et al.
Publicado: (2019)

Antioxidative Effects of Natural Products on Diabetic Cardiomyopathy
por: Yan, Bingdi, et al.
Publicado: (2017)

Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes
por: González, N., et al.
Publicado: (2017)

Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System
por: Lumpuy-Castillo, Jairo, et al.
Publicado: (2020)

Metabolic Alterations in Inherited Cardiomyopathies
por: Sacchetto, Claudia, et al.
Publicado: (2019)

Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography
por: van den Brom, Charissa E, et al.
Publicado: (2009)

Concealed Substrates in Brugada Syndrome: Isolated Channelopathy or Associated Cardiomyopathy?
por: Di Resta, Chiara, et al.
Publicado: (2022)

Gypenosides improve diabetic cardiomyopathy by inhibiting ROS‐mediated NLRP3 inflammasome activation
por: Zhang, Hailong, et al.
Publicado: (2018)

Optogenetic control of ROS production
por: Wojtovich, Andrew P., et al.
Publicado: (2014)

Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors
por: Tuñón, José, et al.
Publicado: (2007)

Altered Calcium Homeostasis Does Not Explain the Contractile Deficit of Diabetic Cardiomyopathy
por: Zhang, Lin, et al.
Publicado: (2008)

Diabetic cardiomyopathy
por: Asghar, Omar, et al.
Publicado: (2009)

Diabetic Cardiomyopathy: Does the Type of Diabetes Matter?
por: Hölscher, Maximilian E., et al.
Publicado: (2016)

Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
por: Longo, Miriam, et al.
Publicado: (2022)

N-Acetylcysteine, an ROS Inhibitor, Alleviates the Pathophysiology of Hyperthyroidism-Induced Cardiomyopathy via the ROS/Ca(2+) Pathway
por: Bao, Mengni, et al.
Publicado: (2022)

Arrhythmogenic right ventricular cardiomyopathy: Electroarchitecture of the substrate
por: Watanabe, Atsuyuki, et al.
Publicado: (2015)

Regulation of Stem Cell Fate by ROS-mediated Alteration of Metabolism
por: Ryu, Jung Min, et al.
Publicado: (2015)

The Alterations of Mitochondrial Function during NAFLD Progression—An Independent Effect of Mitochondrial ROS Production
por: Simões, Inês C. M., et al.
Publicado: (2021)

Predictors and prevention of diabetic cardiomyopathy
por: Chavali, Vishalakshi, et al.
Publicado: (2013)

Mitochondrial Mechanisms in Diabetic Cardiomyopathy
por: Gollmer, Johannes, et al.
Publicado: (2020)

Role of inflammation in diabetic cardiomyopathy
por: Ramesh, Pranav, et al.
Publicado: (2022)

Regulation of Energy Substrate Metabolism in Endurance Exercise
por: Alghannam, Abdullah F., et al.
Publicado: (2021)

The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Effects of ketone bodies on energy expenditure, substrate utilization, and energy intake in humans
por: Fernández-Verdejo, Rodrigo, et al.
Publicado: (2023)

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy
por: da Silva, Jaqueline S., et al.
Publicado: (2022)

Applications of the ROS-Responsive Thioketal Linker for the Production of Smart Nanomedicines
por: Rinaldi, Arianna, et al.
Publicado: (2022)

Noncompaction cardiomyopathy: a substrate for a thromboembolic event
por: Tavares de Melo, Marcelo Dantas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k8qbn7ingn2peq3d9bn9q3tn1u